High-throughput screened kaempferitrin potentiates trastuzumab efficacy in HER2-positive gastric cancer by targeting Cyclooxygenase-2 to inhibit ERK signaling.
2/5 보강
TL;DR
This study shows that kaempferitrin as a promising sensitizer of trastuzumab, which enhances its therapeutic efficacy against HER-positive GC progression by suppressing COX2/ERK signaling.
OpenAlex 토픽 ·
HER2/EGFR in Cancer Research
Gastric Cancer Management and Outcomes
Protease and Inhibitor Mechanisms
This study shows that kaempferitrin as a promising sensitizer of trastuzumab, which enhances its therapeutic efficacy against HER-positive GC progression by suppressing COX2/ERK signaling.
APA
Huiming Zhao, Jumei Yang, et al. (2026). High-throughput screened kaempferitrin potentiates trastuzumab efficacy in HER2-positive gastric cancer by targeting Cyclooxygenase-2 to inhibit ERK signaling.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 154, 158034. https://doi.org/10.1016/j.phymed.2026.158034
MLA
Huiming Zhao, et al.. "High-throughput screened kaempferitrin potentiates trastuzumab efficacy in HER2-positive gastric cancer by targeting Cyclooxygenase-2 to inhibit ERK signaling.." Phytomedicine : international journal of phytotherapy and phytopharmacology, vol. 154, 2026, pp. 158034.
PMID
41797190
Abstract
[BACKGROUND] Trastuzumab is the first-line therapy for human epidermal growth factor receptor-2 (HER2)-positive gastric cancer (GC). However, intrinsic and acquired resistance due to hyperactivation of intracellular signaling pathway such as MEK/ERK pathways limit its clinical benefits. Plant-derived bioactive compounds have emerged as promising candidates to overcome trastuzumab resistance due to their multi-target effects and favorable safety profiles.
[PURPOSE] To identify a small-molecule compound derived from Traditional Chinese Medicine (TCM) that could enhance trastuzumab sensitivity in HER2-positive GC by suppressing ERK hyperactivation.
[METHODS] An ERK kinase translocation reporter (ERK-KTR) was established for screening. Spontaneous gastric tumors derived from Kras;Trp53; Smad4;Anxa10-CreER (KPSA) mice were transplanted into C57BL/6 N mice for evaluating the therapeutic effect of kaempferitrin. We developed a F127-kaempferitrin (FKF) nano-delivery system, and generated patient-derived xenograft (PDX) models using HER2-positive GC tissues from a patient to evaluate efficiency of FKF.
[RESULTS] We identified kaempferitrin as a potentiator of trastuzumab efficacy in HER2-positive GC. Trastuzumab plus kaempferitrin inhibits the proliferation and invasion of SNU-216 cells and impedes tumor growth and lung metastasis in mouse with gastric tumors from KPSA mice. Kaempferitrin targeted COX2 to suppress ERK activation, thereby inhibiting gastric cancer progression and sensitizing trastuzumab therapy via interactions at Glu603, Thr198, and Gln440. Toxicological evaluations show that the combination of trastuzumab and kaempferitrin were well-tolerated, and FKF nanoparticle exhibited potent anti-tumor efficacy in HER2-positive GC PDX models.
[CONCLUSION] Our study shows that kaempferitrin as a promising sensitizer of trastuzumab, which enhances its therapeutic efficacy against HER-positive GC progression by suppressing COX2/ERK signaling.
[PURPOSE] To identify a small-molecule compound derived from Traditional Chinese Medicine (TCM) that could enhance trastuzumab sensitivity in HER2-positive GC by suppressing ERK hyperactivation.
[METHODS] An ERK kinase translocation reporter (ERK-KTR) was established for screening. Spontaneous gastric tumors derived from Kras;Trp53; Smad4;Anxa10-CreER (KPSA) mice were transplanted into C57BL/6 N mice for evaluating the therapeutic effect of kaempferitrin. We developed a F127-kaempferitrin (FKF) nano-delivery system, and generated patient-derived xenograft (PDX) models using HER2-positive GC tissues from a patient to evaluate efficiency of FKF.
[RESULTS] We identified kaempferitrin as a potentiator of trastuzumab efficacy in HER2-positive GC. Trastuzumab plus kaempferitrin inhibits the proliferation and invasion of SNU-216 cells and impedes tumor growth and lung metastasis in mouse with gastric tumors from KPSA mice. Kaempferitrin targeted COX2 to suppress ERK activation, thereby inhibiting gastric cancer progression and sensitizing trastuzumab therapy via interactions at Glu603, Thr198, and Gln440. Toxicological evaluations show that the combination of trastuzumab and kaempferitrin were well-tolerated, and FKF nanoparticle exhibited potent anti-tumor efficacy in HER2-positive GC PDX models.
[CONCLUSION] Our study shows that kaempferitrin as a promising sensitizer of trastuzumab, which enhances its therapeutic efficacy against HER-positive GC progression by suppressing COX2/ERK signaling.
MeSH Terms
Animals; Stomach Neoplasms; Trastuzumab; Humans; Erb-b2 Receptor Tyrosine Kinases; Mice; Cyclooxygenase 2; MAP Kinase Signaling System; Cell Line, Tumor; Mice, Inbred C57BL; Drug Synergism; Female; High-Throughput Screening Assays; Xenograft Model Antitumor Assays
같은 제1저자의 인용 많은 논문 (5)
- Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
- Mechanisms Influencing Neoadjuvant Treatment Decision-Making in Patients With Locally Advanced Gastric Cancer: An Analysis Based on the Ottawa Decision Support Framework.
- Dysregulated inflammatory cytokines in MSM living with HIV who exhibited suboptimal immune reconstitution despite antiretroviral therapy (ART).
- SUMOylation and anticancer drug resistance.
- F-FDG PET-based ensemble deep learning model for the prediction of lymphovascular invasion in colorectal cancer patients.